Human HRASLS3 (PLA2G16) activation kit by CRISPRa
CAT#: GA107668
PLAAT3 CRISPRa kit - CRISPR gene activation of human phospholipase A and acyltransferase 3
Find the corresponding CRISPRi Inhibitor Kit
USD 1,290.00
2 Weeks*
Specifications
Product Data | |
Format | 3gRNAs, 1 scramble ctrl and 1 enhancer vector |
Symbol | PLAAT3 |
Locus ID | 11145 |
Kit Components | GA107668G1, PLAAT3 gRNA vector 1 in pCas-Guide-CRISPRa GA107668G2, PLAAT3 gRNA vector 2 in pCas-Guide-CRISPRa GA107668G3, PLAAT3 gRNA vector 3 in pCas-Guide-CRISPRa 1 CRISPRa-Enhancer vector, SKU GE100056 1 CRISPRa scramble vector, SKU GE100058 |
Disclaimer | The kit is designed based on the best knowledge of CRISPa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc. |
Reference Data | |
RefSeq | NM_001128203, NM_007069 |
Synonyms | AdPLA; H-REV107-1; HRASLS3; HREV107; HREV107-1; HREV107-3; HRSL3 |
Summary | Lipid-modifying enzyme that acts as major regulator of adipocyte lipolysis by catalyzing the release of fatty acids from phospholipids in adipose tissue (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). Shows phospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE) (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). For most substrates, phospholipase A1 activity is much higher than phospholipase A2 activity (PubMed:19047760). Phospholipase activity causes decreased intracellular levels of ether-type lipids, affecting peroxisome metabolism (By similarity). May also have acyltransferase activity: catalyzes both N-acylation of phosphatidylethanolamine to form N-acyl-phosphatidylethanolamine and O-acylation of lyso-phosphatidylcholines to form phosphatidylcholines (PubMed:22605381, PubMed:25383759). The relevance of acyltransferase activity in vivo is however unclear and would require additional evidences (PubMed:22605381, PubMed:25383759). Also has weak lysophospholipase activity. [UniProtKB/Swiss-Prot Function] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
Other Versions
SKU | Description | Size | Price |
---|---|---|---|
KN400242 | PLA2G16 - KN2.0, Human gene knockout kit via CRISPR, non-homology mediated. |
USD 1,290.00 |
{0} Product Review(s)
Be the first one to submit a review